Taking all of this together, biomarkers, including GLP-1, GIP, MCP-1, and IGFBP-7, are valuable in the field of metabolic disorders such as type 2 diabetes (T2D) and obesity, and they can also be used as predictive models, because they provide specific information about the underlying mechanisms and pathophysiological processes of these conditions. This evidence concerns the gene IGFBP7 and metabolic disease.